ALX Oncology Holdings Stock
ALX Oncology Holdings Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jason Lettmann
- Employees
- 48
- Market cap
- $147 M
- IPO
- 17/07/2020
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including…
ALX Oncology Holdings stock: price history
1D
+6.0%
1W
-15.2%
1M
-39.8%
6M
-36.5%
YTD
-6.2%
1Y
-35.8%
2Y
-32.1%
5Y
-98.2%
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~6% stronger price swings than usual
ALX Oncology Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 04/09/2026.
Business model & megatrends
Not calculated yet.
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing novel cancer therapies. At its core is the drug candidate Evorpacept, a CD47-blocking biologic currently being studied for the treatment of gastric cancer and, through partnerships with companies such as Sanofi and Jazz Pharmaceuticals, for other cancer indications. The business model is based on developing proprietary therapeutics through research and clinical trials, leveraging licensing agreements and strategic partnerships.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Jazz Pharmaceuticals plcDescription
SanofiDescriptionAsk the agents about ALX Oncology Holdings
Analyst assessment of ALX Oncology Holdings
PRICE TARGET LOW
US$1.50
CONSENSUS
US$17.90
MEDIAN
US$21.00
PRICE TARGET HIGH
US$38.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 10/03/2026
ALX Oncology Holdings stock metrics
P/E
-0.94
P/B
1.06
EV/EBITDA
-1.69
RETURN ON EQUITY
-13.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
70.6%
FLOAT SHARES
97,652,462
AVG. DAILY VOLUME (30D)
1,427,374
Insider transactions (SEC)
Wong Shelly
Lettmann Jason
Wong Shelly
Attention
Price since yesterday: +6.0%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about ALX Oncology Holdings stock
What does ALX Oncology Holdings do?
ALX Oncology Holdings Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jason Lettmann, the company employs around 48 people.
The IPO was on 17/07/2020; the stock trades on NASDAQ under the ticker ALXO.
What do analysts say about ALX Oncology Holdings stock?
7 analysts rate the stock, the consensus is Buy (as of 10/03/2026).
The average price target is US$17.90, ranging from US$1.50 to US$38.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does ALX Oncology Holdings report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 6% stronger than usual.
Does ALX Oncology Holdings pay a dividend?
No, ALX Oncology Holdings currently does not pay a dividend.
Which stocks are comparable to ALX Oncology Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ALX Oncology Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess ALX Oncology Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.